Drug Profile
A 01 - IC 01
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Hangzhou Converd
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Solid-tumours(Late-stage disease) in China
- 02 Apr 2018 Hangzhou Converd and The Second Hospital of Jia Xing plans a phase I trial for Gastrointestinal cancer (Combination therapy, Late-stage disease, In adults, In the elderly) in April 2018 (NCT03474861)
- 21 Mar 2018 Hangzhou Converd in collaboration with The Second People's Hospital of Yibin plans a phase I trial of A 01 in combination with immune cells IC 01 for Solid Tumours (Late-stage disease) in China, in April 2018(NCT03472352)